Gapping up
In reaction to strong earnings/guidance:
- SAGE +24.2%, FOE +16.8%, APYX +13.3%, ICUI +11.2%, SE +10.1%, ROK +7.8%, GO +7.5%, GTT +6.3%, INFN +4.4%, FNV +3.5%, VOD +3.1%, DHI +3%, PSN +2.5%, DXC +2.1%, CRON +2%, LIN +1.6%, JMIA +1.5%, FGEN +1%, EDIT +0.8% (also - Editas Medicine & Celgene (CELG) amend collaboration, Editas to receive payment of $70 mln)
M&A news:
- BREW +122.8% (Craft Brew Alliance shares to be purchased by Anheuser-Busch (BUD) for $16.50/share in cash)
- LTS +22.4% (to be acquired by Advisor Group for $3.50/share in cash)
- KEM +12.5% (Yageo will acquire all of the outstanding shares of KEMET's common stock for US$27.20 per share in an all-cash transaction valued at US $1.8 billion)
- BUD +1.2% (Craft Brew Alliance shares to be purchased by Anheuser-Busch (BUD) for $16.50/share in cash)
Other news:
- KDMN +20.4% (announces that KD025 met primary endpoint at interim analysis of pivotal trial in chronic graft-versus-host disease; call today at 5:00 p.m. Eastern Time), RKDA +6.3% (attributed to HB4 soybean approval in Paraguay)
- BZUN +1.4% (total order value settled through payment gateways on all of the Company's e-commerce channels reached a record RMB10.06 bln on Singles Day 2019)
- TUP +1.2% (names Christopher D. O'Leary interim CEO)
Analyst comments:
- CRWD +3.5% (upgraded to Neutral from Sell at Goldman)
- RCII +2.1% (upgraded to Buy from Hold at Stifel)
- LYV +1.2% (upgraded to Outperform from In-line at Evercore ISI)
- XRX +0.6% (upgraded to Neutral from Underweight at JP Morgan)
- PANW +0.6% (initiated with a Buy at Goldman)